Noteworthy, in a proof-of-concept clinical trial with 39 patients carrying the G551D mutation, Ivacaftor administered orally exhibited a within-subject improvement in CFTR markers and lung function, suggesting that potentiators may be a viable therapeutic approach for the treatment of at least some CF patients (Accurso et al, 2010). Here, CFTR is linked to cystic fibrosis.